Duodenal neuroendocrine tumour associated with minimal change glomerulonephritis. Issue 8 (30th August 2019)

• Record Type: Journal Article
• Authors: Montague, Emily; Hockenhull, Kimberley; Lamarca, Angela; Al-Sayed, Tamer; Hubner, Richard A
• Is Part Of: BMJ case reports. Volume 12:Issue 8(2019)
• Publication Date: 2019-08-30
• Subjects: endocrine cancer -- nephrotic syndrome -- proteinurea -- small intestine cancer; Medicine -- Case studies -- Periodicals; 610.5
• DOI: 10.1136/bcr-2018-227987
• Languages: English
• ISSNs: 1757-790X

Abstract

Abstract : Paraneoplastic glomerular disease is an increasingly well-recognised entity, and a wide range of both solid and haematological malignancies have been implicated. The most common glomerular disease associated with cancer is membranous nephropathy. Only a few case reports have described an association between neuroendocrine tumours (NETs) and glomerulonephritis and only one paediatric case in relation to minimal change disease. A 76-year-old woman with a well-differentiated duodenal NET presented with nephrotic syndrome and renal biopsy was suggestive of minimal change glomerulonephritis. Standard therapy with corticosteroids brought little benefit, but a dramatic improvement was seen following initiation of systemic anticancer therapy with lanreotide, a somatostatin analogue. Less than 1 month after initiation of lanreotide, the patient was no longer in a nephrotic state, and after a further 2 months of follow-up had shown no sign of relapse.